Skip to main content

Vanderbilt Vaccine Center

Flu’s “hidden target” may lead to universal vaccine: study

May. 16, 2019—The flu mutates so quickly that we need a new vaccine every year, but Vanderbilt scientists have found a vulnerable part of the virus that doesn't mutate as much.

Read more


Vanderbilt Vaccine Center Seminar Series: Brandon DeKosky May 6

Apr. 30, 2019—The Vanderbilt Vaccine Center Seminar Series presents Brandon DeKosky, assistant professor of chemical engineering and pharmaceutical chemistry at the University of Kansas, on Monday, May 6.

Read more


VUMC chikungunya antibody set to enter clinical trial

Feb. 21, 2019—A monoclonal antibody against the chikungunya virus developed by researchers at Vanderbilt University Medical Center is the first monoclonal antibody encoded by messenger RNA to enter a clinical trial.

Read more


Researchers push forward frontiers of vaccine science

Feb. 13, 2019—Using sophisticated gene sequencing and computing techniques, Vanderbilt researchers have achieved a first-of-its-kind glimpse into how the body’s immune system gears up to fight off infection.

Read more


Designing antibodies to fight the flu

Jan. 31, 2019—James Crowe Jr. and colleagues have developed a new computational method that may allow researchers to develop flu antibodies that can protect against more strains of the disease.

Read more


VUMC scientists ‘sprint’ to find anti-Zika antibodies

Jan. 25, 2019—Scientists at Vanderbilt University Medical Center and colleagues in Boston, Seattle and St. Louis are racing to develop — in a mere 90 days — a protective antibody-based treatment that can stop the spread of the Zika virus.

Read more


Discovery could lead to neutralizing West Nile virus

Dec. 7, 2018—Research led by James Crowe, Jr., could lead to the first effective treatment for this dangerous mosquito-transmitted infection.

Read more


Team isolates antibodies that neutralize GI bug norovirus

Aug. 30, 2018—The discovery of these antibodies could significantly improve the diagnosis and treatment of the leading cause of stomach illness in the world.

Read more


Poster session Friday will feature work on next-gen vaccines

Aug. 6, 2018—The computer-aided design and engineering of antibodies and vaccine candidates that can neutralize viral scourges like influenza and Ebola will be the topic of an Aug. 17 poster session presented by the Vanderbilt Center for Structural Biology and the Vanderbilt Vaccine Center.

Read more


Team finds potent antibodies against three Ebola viruses

Jul. 19, 2018—Researchers led by James Crowe Jr. are a step closer to developing a broadly effective antibody treatment against the three major Ebola viruses that cause lethal disease in humans. The hope is that the antibodies — like heat-seeking missiles — would seek out and destroy the viruses before they can wreak havoc in the body.

Read more


A “public” target for HIV

Jun. 8, 2018—Common sequences of antibodies against HIV may be key to developing a successful vaccine strategy for the virus.

Read more


New target to stop Ebola

May. 21, 2018—A new Vanderbilt study suggests it may be possible to develop antibody therapies or a universal vaccine effective against multiple Ebola virus family members.

Read more


Upcoming Events

MORE EVENTS »